UK markets closed

Xeris Pharmaceuticals, Inc. (XERS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.4350+0.2450 (+7.68%)
At close: 4:00PM EDT

3.4500 +0.02 (0.44%)
After hours: 7:33PM EDT

Full screen
Trade prices are not sourced from all markets
Previous close3.1900
Open3.1600
Bid3.3500 x 3000
Ask3.4400 x 1800
Day's range3.1000 - 3.5000
52-week range2.4500 - 7.9400
Volume4,333,213
Avg. volume2,435,379
Market cap227.859M
Beta (5Y monthly)1.82
PE ratio (TTM)N/A
EPS (TTM)-2.1370
Earnings date13 May 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est11.25
  • Xeris Pharmaceuticals (XERS) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    Xeris Pharmaceuticals (XERS) Reports Q1 Loss, Tops Revenue Estimates

    Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of 3.23% and 6.42%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights

    Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced financial results for the first quarter 2021 and recent highlights.

  • Business Wire

    Xeris Pharmaceuticals to Webcast Upcoming Presentations

    Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will participate in following upcoming virtual events: